C J Park1, K Han2, H Kim2, S S Ahn3, D Choi4, Y W Park2, J H Chang5, S H Kim6, S Cha7, S-K Lee2. 1. From the Department of Radiology (C.J.P.), Yonsei University College of Medicine, Seoul, Korea. 2. Department of Radiology (K.H., H.K., S.S.A., Y.W.P., S.-K.L.), Research Institute of Radiological Sciences, Center for Clinical Imaging Data Science. 3. Department of Radiology (K.H., H.K., S.S.A., Y.W.P., S.-K.L.), Research Institute of Radiological Sciences, Center for Clinical Imaging Data Science sungsoo@yuhs.ac. 4. Department of Computer Science (D.C.), Yonsei University, Seoul, Korea. 5. Department of Neurosurgery (J.H.C.). 6. Department of Pathology (S.H.K.), Yonsei University College of Medicine, Seoul, Korea. 7. Department of Radiology and Biomedical Imaging (S.C.), University of California San Francisco, San Francisco, California.
Abstract
BACKGROUND AND PURPOSE: Isocitrate dehydrogenase (IDH) wild-type lower-grade gliomas (histologic grades II and III) with epidermal growth factor receptor (EGFR) amplification or telomerase reverse transcriptase (TERT) promoter mutation are reported to behave similar to glioblastoma. We aimed to evaluate whether MR imaging features could identify a subset of IDH wild-type lower-grade gliomas that carry molecular features of glioblastoma. MATERIALS AND METHODS: In this multi-institutional retrospective study, pathologically confirmed IDH wild-type lower-grade gliomas from 2 tertiary institutions and The Cancer Genome Atlas constituted the training set (institution 1 and The Cancer Genome Atlas, 64 patients) and the independent test set (institution 2, 57 patients). Preoperative MRIs were analyzed using the Visually AcceSAble Rembrandt Images and radiomics. The molecular glioblastoma status was determined on the basis of the presence of EGFR amplification and TERT promoter mutation. Molecular glioblastoma was present in 73.4% and 56.1% in the training and test sets, respectively. Models using clinical, Visually AcceSAble Rembrandt Images, and radiomic features were built to predict the molecular glioblastoma status in the training set; then they were validated in the test set. RESULTS: In the test set, a model using both Visually AcceSAble Rembrandt Images and radiomic features showed superior predictive performance (area under the curve = 0.854) than that with only clinical features or Visually AcceSAble Rembrandt Images (areas under the curve = 0.514 and 0.648, respectively; P < . 001, both). When both Visually AcceSAble Rembrandt Images and radiomics were added to clinical features, the predictive performance significantly increased (areas under the curve = 0.514 versus 0.863, P < .001). CONCLUSIONS: MR imaging features integrated with machine learning classifiers may predict a subset of IDH wild-type lower-grade gliomas that carry molecular features of glioblastoma.
BACKGROUND AND PURPOSE: Isocitrate dehydrogenase (IDH) wild-type lower-grade gliomas (histologic grades II and III) with epidermal growth factor receptor (EGFR) amplification or telomerase reverse transcriptase (TERT) promoter mutation are reported to behave similar to glioblastoma. We aimed to evaluate whether MR imaging features could identify a subset of IDH wild-type lower-grade gliomas that carry molecular features of glioblastoma. MATERIALS AND METHODS: In this multi-institutional retrospective study, pathologically confirmed IDH wild-type lower-grade gliomas from 2 tertiary institutions and The Cancer Genome Atlas constituted the training set (institution 1 and The Cancer Genome Atlas, 64 patients) and the independent test set (institution 2, 57 patients). Preoperative MRIs were analyzed using the Visually AcceSAble Rembrandt Images and radiomics. The molecular glioblastoma status was determined on the basis of the presence of EGFR amplification and TERT promoter mutation. Molecular glioblastoma was present in 73.4% and 56.1% in the training and test sets, respectively. Models using clinical, Visually AcceSAble Rembrandt Images, and radiomic features were built to predict the molecular glioblastoma status in the training set; then they were validated in the test set. RESULTS: In the test set, a model using both Visually AcceSAble Rembrandt Images and radiomic features showed superior predictive performance (area under the curve = 0.854) than that with only clinical features or Visually AcceSAble Rembrandt Images (areas under the curve = 0.514 and 0.648, respectively; P < . 001, both). When both Visually AcceSAble Rembrandt Images and radiomics were added to clinical features, the predictive performance significantly increased (areas under the curve = 0.514 versus 0.863, P < .001). CONCLUSIONS: MR imaging features integrated with machine learning classifiers may predict a subset of IDH wild-type lower-grade gliomas that carry molecular features of glioblastoma.
Authors: Y W Park; K Han; S S Ahn; S Bae; Y S Choi; J H Chang; S H Kim; S-G Kang; S-K Lee Journal: AJNR Am J Neuroradiol Date: 2017-11-09 Impact factor: 3.825
Authors: David A Gutman; Lee A D Cooper; Scott N Hwang; Chad A Holder; Jingjing Gao; Tarun D Aurora; William D Dunn; Lisa Scarpace; Tom Mikkelsen; Rajan Jain; Max Wintermark; Manal Jilwan; Prashant Raghavan; Erich Huang; Robert J Clifford; Pattanasak Mongkolwat; Vladimir Kleper; John Freymann; Justin Kirby; Pascal O Zinn; Carlos S Moreno; Carl Jaffe; Rivka Colen; Daniel L Rubin; Joel Saltz; Adam Flanders; Daniel J Brat Journal: Radiology Date: 2013-02-07 Impact factor: 11.105
Authors: A Gupta; R J Young; A D Shah; A D Schweitzer; J J Graber; W Shi; Z Zhang; J Huse; A M P Omuro Journal: Clin Neuroradiol Date: 2014-01-29 Impact factor: 3.649
Authors: M Zhang; L Tam; J Wright; M Mohammadzadeh; M Han; E Chen; M Wagner; J Nemalka; H Lai; A Eghbal; C Y Ho; R M Lober; S H Cheshier; N A Vitanza; G A Grant; L M Prolo; K W Yeom; A Jaju Journal: AJNR Am J Neuroradiol Date: 2022-03-31 Impact factor: 3.825
Authors: Michael Zhang; Samuel W Wong; Jason N Wright; Sebastian Toescu; Maryam Mohammadzadeh; Michelle Han; Seth Lummus; Matthias W Wagner; Derek Yecies; Hollie Lai; Azam Eghbal; Alireza Radmanesh; Jordan Nemelka; Stephen Harward; Michael Malinzak; Suzanne Laughlin; Sebastien Perreault; Kristina R M Braun; Arastoo Vossough; Tina Poussaint; Robert Goetti; Birgit Ertl-Wagner; Chang Y Ho; Ozgur Oztekin; Vijay Ramaswamy; Kshitij Mankad; Nicholas A Vitanza; Samuel H Cheshier; Mourad Said; Kristian Aquilina; Eric Thompson; Alok Jaju; Gerald A Grant; Robert M Lober; Kristen W Yeom Journal: Neurosurgery Date: 2021-10-13 Impact factor: 5.315
Authors: Zhicong Li; Lena Kaiser; Adrien Holzgreve; Viktoria C Ruf; Bogdana Suchorska; Vera Wenter; Stefanie Quach; Jochen Herms; Peter Bartenstein; Jörg-Christian Tonn; Marcus Unterrainer; Nathalie L Albert Journal: Eur J Nucl Med Mol Imaging Date: 2021-09-07 Impact factor: 9.236
Authors: Vittorio Stumpo; Lelio Guida; Jacopo Bellomo; Christiaan Hendrik Bas Van Niftrik; Martina Sebök; Moncef Berhouma; Andrea Bink; Michael Weller; Zsolt Kulcsar; Luca Regli; Jorn Fierstra Journal: Cancers (Basel) Date: 2022-03-05 Impact factor: 6.639